|

LMV-12(HE003) Clinical Trials

1 actively recruiting trial

Also known as: Osimertinib

Pipeline

Phase 1/2: 1

Top Sponsors

  • Hunan Province Tumor Hospital1

Indications

  • EGF-R Positive Non-Small Cell Lung Cancer1
  • MET Amplification1
  • RET Gene Mutation1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Other1 trial

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.